Evidence map›Paper›PMID 28804273›Full record

ArticleBioinorganic chemistry and applications2017

Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin.

Yulia N Nosova, Ilia V Zenin, Varvara P Maximova, Ekaterina M Zhidkova, Kirill I Kirsanov, Ekaterina A Lesovaya, Anna A Lobas, Mikhail V Gorshkov, Olga N Kovaleva, Elena R Milaeva and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioinorganic chemistry and applications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Ru(III) Complexes with Lonidamine-Modified Ligands.International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Yulia N NosovaDepartment of Medicinal Chemistry and Fine Organic Synthesis, Lomonosov Moscow State University, Leninskie Gory 1/3, Moscow 119991, Russia.
Ilia V ZeninDepartment of Medicinal Chemistry and Fine Organic Synthesis, Lomonosov Moscow State University, Leninskie Gory 1/3, Moscow 119991, Russia.
Varvara P MaximovaBlokhin Cancer Research Center, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Ekaterina M ZhidkovaBlokhin Cancer Research Center, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Kirill I KirsanovBlokhin Cancer Research Center, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Ekaterina A LesovayaBlokhin Cancer Research Center, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Anna A LobasInstitute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Leninsky Pr. 38, Bld.2, Moscow 119334, Russia.
Mikhail V GorshkovInstitute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Leninsky Pr. 38, Bld.2, Moscow 119334, Russia.
Olga N KovalevaI.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Elena R MilaevaDepartment of Medicinal Chemistry and Fine Organic Synthesis, Lomonosov Moscow State University, Leninskie Gory 1/3, Moscow 119991, Russia.ORCID 0000-0002-5489-3866
Markus GalanskiFaculty of Chemistry, Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1019 Vienna, Austria.
Bernhard K KepplerFaculty of Chemistry, Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1019 Vienna, Austria.
Alexey A NazarovDepartment of Medicinal Chemistry and Fine Organic Synthesis, Lomonosov Moscow State University, Leninskie Gory 1/3, Moscow 119991, Russia.ORCID 0000-0002-5821-1658
Lomonosov Moscow State University · RURussian Cancer Research Center NN Blokhin · RUInstitute of Energy Problems of Chemical Physics · RUUniversity of Vienna · ATSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the synthesis and cytotoxic potencies of new Pt(IV) complexes with bexarotene, an anticancer drug that induces cell differentiation and apoptosis via selective activation of retinoid X receptors. In these complexes bexarotene is positioned as an axial ligand. The complex of one bexarotene ligand attached to Pt(IV) oxaliplatin moiety was potent whereas its counterpart carrying two bexarotene ligands was inactive.

Identifiers

PMID28804273
PMCPMC5540250
OpenAlexW2738018353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.